

PATENT
830010-2006.2AMENDMENT

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

IN THE CLAIMS:

1. (Currently amended) A topical pharmaceutical composition comprising ketamine and morphine and a pharmaceutically acceptable topical excipient, wherein the which provides delivery of the ketamine and morphine is delivered to peripheral opiate receptors and not to central opiate receptors.

2-3. (Cancelled)

4. (Withdrawn)

5-6. (Cancelled)

7. (Original) The topical pharmaceutical composition according to claim 1 further comprising a local anesthetic.

8. (Original) The topical pharmaceutical composition according to claim 7, wherein the local anesthetic is selected from the group consisting of lidocaine, bupivacaine, mepivacaine, ropivacaine, tetracaine and benzocaine.

9. (Currently Amended) A method of providing peripheral analgesia and not central or systemic analgesia to a mammal comprising topically administering a tolerance-attenuating dose of ketamine prior to, concurrently with, or following topically ~~administering~~ administering morphine, wherein the morphine that functions through an peripheral opiate receptor.

10-12. (Cancelled)

13. (Withdrawn)

14. (Previously Amended) The method according to claim 9, wherein ketamine is administered in a dose of about 0.1 % to about 5%, by weight, of total weight of ketamine and morphine.

15. (Previously Amended) A method of providing tolerance attenuating analgesia to a mammal with pre-existing tolerance to an analgesic comprising topically administering an effective tolerance-attenuating, peripherally and not centrally or systemically, analgesic dose of ketamine concurrently or following topically administering morphine that functions through an opiate receptor.

PATENT
830010-2006.2

C1
Cont'd

16. (Previously Amended) A pharmaceutical tolerance-attenuating analgesic kit comprising:

(a) a topical or systemic pharmaceutical composition comprising morphine that functions through an opiate receptor; and

(b) a topical pharmaceutical composition comprising a tolerance-attenuating, peripherally but not centrally or systemically analgesic dose, of ketamine.

17. (Withdrawn)

18. (Cancelled)
